Excellent course on strategies for drug commercialization including pharmacoeconomics and how pharma partners with other stakeholders to accomplish this. Excellent examples of drug lifecycles.
Excellent content and lecturers. Great course to finish this specialization. I strongly recommend the three courses for those interested in pursuing a career in pharma or willing to shift.
By Mohamed T H•
Much better than the Drug Discovery and Drug Development courses in this specialization. In particular, the 2nd half of 3rd week was understandable and clearly taught. That part I think was later added and was not a part of the lectures otherwise used in these courses. That section really showed the potential of these courses which unfortunately was not reached due to the lectures that were used. Most of the time the presentation slides were filled with so many texts that you would wonder if its a presentation or an article. This course was better than the previous two courses though. After completing the three courses I feel that these courses could be much better if the course providers would improve the presentations used. Nonetheless, the course was informative. But there's only so much that one can absorb with so busy slides with not so attractive layout.
The course is exremely useful and packs a lot of knowledge, however it's regrettable that the course was made in 2013-2014, and since then it was not updated. The pauses at the beginning of videos make you unsure whether you hit the right button, so I think that videos could be better edited. I found that lectures with Remi Brouard were not focussed and sometimes repetitive with what Dr Ettouti said already on industry collaboration. Overall, I found the course extremely useful, providing lot of insightful knowledge.
By Kierstin L•
Etouillie was great and his experience commentary made the course more interesting. His biosimilar section is highly pertinent to the US current situation with lawsuits flying every which way. I do wish more regulatory process steps were included. The start up success last section was not helpful. More just seemed like a quick review article one could read about an approved drug and the story of someone bragging about how lucky they were.
By Danna F M•
The course was very interesting and cover differents topics to give me an overview of drug commercialization in USA. In addition, the experiences shared from the each professor was excelent. However, I didn't know that the majority of topics were made in 2013. So this information was missing when I applied for this course.
By George L•
I found this course to be very engaging and informative about the Drug Development Process. However, most of the information is outdated - the course was recorded in 2015 and a lot has changed in pharma since then. I would give it a 5-stare rating if I had taken the course say 4-5 years ago.
By Alexander B•
Most of materials are quite outdated and also quality of presentations sometimes was not that good.
By Richik N M•
Not enough materials on HEOR and Phase IV studies. Week 4's lectures were redundant.
By Saudamini R•
Its a wonderful course, but i would request the faculty to include more recent data
By Muhammed T k•
some lectures are not understand
By Vincent L•
It was alright, couldve given more examples and cases
By yousef e•
i think part one in week 4 is too bad
By Aline M B M•